Skip to main content
      RT @uptoTate: Alternate-day GC in IgG4-RD reduced GC-related AEs (adjusted for cumulative GC doses) w/o increase in dz f

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Alternate-day GC in IgG4-RD reduced GC-related AEs (adjusted for cumulative GC doses) w/o increase in dz flares particularly when combined w/ immunosuppressants. Possible new tx strategy for clinic? Need more data re: long-term dz Abs 0128 #ACR22 @RheumNow https://t.co/a1c1ZDeOCK https://t.co/3deUugpcVW
      RT @bella_mehta: CAR-T cells in #sle - talk of the town this year!
      reset the immune system?
      deep depletion CD19+ B cell

      Bella Mehta bella_mehta

      3 years 10 months ago
      CAR-T cells in #sle - talk of the town this year! reset the immune system? deep depletion CD19+ B cell and tissue plasmablasts. 5 pts with SLE - drug free remission at 8 months. Costs and risks still limiting use widely. year in review #ACR22 @rheumnow https://t.co/ophgPjCDuF
      RT @bella_mehta: Data from - CARRA registry sJIA-Lung Disease cohort -
      Affects 1 in 20 pts - Interstitial lung disease

      Bella Mehta bella_mehta

      3 years 10 months ago
      Data from - CARRA registry sJIA-Lung Disease cohort - Affects 1 in 20 pts - Interstitial lung disease (ILD) and pulmonary alveolar proteinosis (PAP). 13 pts - common features - tachypnea, clubbing, cough, finger and toe erythema #MAS in 56% pts. @RheumNow #ACR22 abst#0864 https://t.co/Q8fEzOkjJ7
      RT @RichardPAConway: Sode et al Mortality in GCA. Dominated by CV disease and higher than controls. Less cancer than con

      Richard Conway RichardPAConway

      3 years 10 months ago
      Sode et al Mortality in GCA. Dominated by CV disease and higher than controls. Less cancer than controls @rheumnow #ACR22 Abstr#0467 https://t.co/TsfTWFRxJ2 https://t.co/lCZgVTpKUY
      RT @RichardPAConway: Kaeley et al. Evaluation of success of RA treatment. 69% LDA, 17% MDA, 14% HDA. Common barriers - m

      Richard Conway RichardPAConway

      3 years 10 months ago
      Kaeley et al. Evaluation of success of RA treatment. 69% LDA, 17% MDA, 14% HDA. Common barriers - medication access 27%, non-adherence 20%, co-morbidities 20%, non-inflammatory pain 13% @rheumnow #ACR22 Abstr#0077 https://t.co/c7euuzSx1m https://t.co/9ZN14ph5kI
      RT @ericdeinmd: @AlexisOgdie at #ACR22:
      Ab0189 Ignite 🔥
      PEST screening in patients with PsO w/o diagnosis of PsA - ca

      Eric Dein ericdeinmd

      3 years 10 months ago
      @AlexisOgdie at #ACR22: Ab0189 Ignite 🔥 PEST screening in patients with PsO w/o diagnosis of PsA - captures pts at highest risk. Decrease QoL, higher co-morbdities High sensitivity test for screening But is it capturing other co-morbidities (obesity, depression?) @RheumNow
      RT @RHEUMarampa: What factors influence visit preferences in pts w/ rheumatic dse? @rheumarhyme @doktora_ging
      Interesti

      sheila RHEUMarampa

      3 years 10 months ago
      What factors influence visit preferences in pts w/ rheumatic dse? @rheumarhyme @doktora_ging Interesting findings by Dr MDanila et al: 👉In-person visits due to org/clinic level influences 👉#telemedicine visits due to individual level influences #ACR22 @RheumNow ABST0193 https://t.co/HcCUeahH8L
      RT @DrPetryna: Pregnancy associated back pain and fatigue during 3rd trimester of pregnancy may affect accuracy of BASD

      Olga Petryna DrPetryna

      3 years 10 months ago
      Pregnancy associated back pain and fatigue during 3rd trimester of pregnancy may affect accuracy of BASDAI score in women with AS. Morning stiffness has the highest classification value #ABS0374 #ACR22 @RheumNow https://t.co/DozZ6bxSU3
      RT @RichardPAConway: Levinson et al. Comparative risks of Alzheimers in inflammatory diseases. SLE (OR 1.31) and IBD (OR

      Richard Conway RichardPAConway

      3 years 10 months ago
      Levinson et al. Comparative risks of Alzheimers in inflammatory diseases. SLE (OR 1.31) and IBD (OR 1.17) higher risk than controls, RA, or PsO/PsA @rheumnow #ACR22 Abstr#0062 https://t.co/PbRa033e0L https://t.co/ENycKG4cyQ
      RT @uptoTate: Mechanistic target of rapamycin (mTOR) inhibitors may be successful tx of sarcoidosis. Abs 0136 is an inte

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Mechanistic target of rapamycin (mTOR) inhibitors may be successful tx of sarcoidosis. Abs 0136 is an interesting study yielding more questions than answers. #ACR22 @RheumNow https://t.co/0Q260CGw3r https://t.co/LepPOrq7Gv
      RT @RichardPAConway: Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 pa

      Richard Conway RichardPAConway

      3 years 10 months ago
      Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 patients. Sustained remission 78.2% optimised group (vs 66.7%). @rheumnow #ACR22 Abstr#0474 https://t.co/jPRy4RjfJA https://t.co/b1CP8pFwhJ
      RT @synovialjoints: Adding MTX to Pegloticase for 52 wks in gout
      ◦ Improved response rate by 30%
      ◦ Reduced disconti

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      Adding MTX to Pegloticase for 52 wks in gout ◦ Improved response rate by 30% ◦ Reduced discontinuation rate by 40% ◦ Greater resolution of tophi by 20% ◦ Similar safety profile in MTX vs non-MTX groups Botson J MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow
      RT @RichardPAConway: Fussner et al. Alpha1-antitrypsin alleles in AAV. Deficiency alleles in 16%. More likely MPA, MPO+.

      Richard Conway RichardPAConway

      3 years 10 months ago
      Fussner et al. Alpha1-antitrypsin alleles in AAV. Deficiency alleles in 16%. More likely MPA, MPO+. Less likely MSK symptoms, granulomatous disease @rheumnow #ACR22 Abstr#0439 https://t.co/Zi7H5UaolS https://t.co/Z04TvugnnE
      ×